Details for Patent: 8,022,279
✉ Email this page to a colleague
Which drugs does patent 8,022,279 protect, and when does it expire?
Patent 8,022,279 protects VYXEOS and is included in one NDA.
This patent has thirteen patent family members in eleven countries.
Summary for Patent: 8,022,279
| Title: | Liposomal formulations of anthracycline agents and cytidine analogs |
| Abstract: | Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent. |
| Inventor(s): | Mayer; Lawrence (North Vancouver, CA), Johnstone; Sharon (Vancouver, CA), Harasym; Troy (North Vancouver, CA) |
| Assignee: | Celator Pharmaceuticals, Inc. (Princeton, NJ) |
| Application Number: | 11/587,112 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 8,022,279
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,022,279
| PCT Information | |||
| PCT Filed | April 22, 2005 | PCT Application Number: | PCT/CA2005/000625 |
| PCT Publication Date: | November 03, 2005 | PCT Publication Number: | WO2005/102359 |
International Family Members for US Patent 8,022,279
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1744764 | ⤷ Sign Up | 122018000134 | Germany | ⤷ Sign Up |
| European Patent Office | 1744764 | ⤷ Sign Up | 300960 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1744764 | ⤷ Sign Up | 2018C/045 | Belgium | ⤷ Sign Up |
| European Patent Office | 1744764 | ⤷ Sign Up | 46/2018 | Austria | ⤷ Sign Up |
| European Patent Office | 1744764 | ⤷ Sign Up | C201830057 | Spain | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
